Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Sirana Pharma General Information
Sirana Pharma is developing innovative therapies for musculoskeletal disorders using a proprietary microRNA-targeting platform. The company has entered into a collaborative research agreement with Pfizer to investigate treatments for rare bone diseases. Its approach aims at substantial regenerative recovery of diseased muscle and bone tissue. Clinical results have not been disclosed publicly as of the latest available information.
Drug Pipeline
Pre-clinical
Key Partnerships
Pfizer Inc. (collaborative research agreement on rare bone disease)
Sirana Pharma Funding
No funding data available
To view Sirana Pharma's complete valuation and funding history, request access »